LXEO (Lexeo Therapeutics) 5-Year EBITDA Growth Rate: -50.90% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LXEO Lexeo Therapeutics Inc LXEO
12 GF Score
Price $5.01
! 3 Warning Signs
View Full Analysis

What is Lexeo Therapeutics 5-Year EBITDA Growth Rate?

Lexeo Therapeutics LXEO -2.34% 12 5-Year EBITDA Growth Rate is -50.90% as of Jun. 2026. GuruFocus rates LXEO with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

Lexeo Therapeutics's EBITDA per Share for the three months ended in Jun. 2026 was $-0.30.

During the past 3 years, the average EBITDA Per Share Growth Rate was 7.60% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -50.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Lexeo Therapeutics was 7.60% per year. The lowest was -304.20% per year. And the median was -14.60% per year.

Lexeo Therapeutics  (NAS:LXEO) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Lexeo Therapeutics 5-Year EBITDA Growth Rate Related Terms

LXEO vs IKT, XFOR, DMAC: 5-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, Lexeo Therapeutics's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lexeo Therapeutics 5-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexeo Therapeutics's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Lexeo Therapeutics's 5-Year EBITDA Growth Rate falls into.


LXEO
12GF Score
Lexeo Therapeutics Inc LXEO
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lexeo Therapeutics 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of -50.90% mean?
Lexeo Therapeutics (LXEO) has a 5-Year EBITDA Growth Rate of -50.90% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Lexeo Therapeutics and its competitors.
Is Lexeo Therapeutics' 5-Year EBITDA Growth Rate too high?
Lexeo Therapeutics' current 5-Year EBITDA Growth Rate is -50.90%. Overall, Lexeo Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Lexeo Therapeutics' 5-Year EBITDA Growth Rate compare to IKT and XFOR?
Lexeo Therapeutics' 5-Year EBITDA Growth Rate of -50.90% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Lexeo Therapeutics and its competitors. Lexeo Therapeutics's current 5-Year EBITDA Growth Rate is -50.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexeo Therapeutics stock overvalued right now?
Lexeo Therapeutics (LXEO) has a current 5-Year EBITDA Growth Rate of -50.90%. The current 5-Year EBITDA Growth Rate is -50.90%. Lexeo Therapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Lexeo Therapeutics (LXEO), the current 5-Year EBITDA Growth Rate is -50.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lexeo Therapeutics Business Description

Address 345 Park Avenue South, Floor 6, New York, NY, USA, 10010
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
12GF Score

Get the complete analysis for LXEO

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.01
Price